Evidence map›Paper›PMID 23349794›Full record

ArticlePloS one2013

Activation of p21 by HDAC inhibitors requires acetylation of H2A.Z.

Luca Bellucci, Mathieu Dalvai, Silvia Kocanova, Fatima Moutahir, Kerstin Bystricky

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 43 citations in OpenAlex.

  1. Article
  2. Review
  3. CDKN1A/p21 in Breast Cancer: Part of the Problem, or Part of the Solution?International journal of molecular sciences · 2023
    Review
  4. Recent advancement of HDAC inhibitors against breast cancer.Medical oncology (Northwood, London, England) · 2023
    Review
  5. Article
  6. Article
  7. HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer.Pharmaceuticals (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. The histone variant H2A.Z in gene regulation.Epigenetics & chromatin · 2019
    Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Luca BellucciLaboratoire de Biologie Moléculaire Eucaryote, Université de Toulouse, Toulouse, France.
Mathieu Dalvai
Silvia Kocanova
Fatima Moutahir
Kerstin Bystricky
Centre National de la Recherche Scientifique · FRLaboratoire de Biologie Moléculaire des Eucaryotes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differential positioning of the histone variant H2A.Z in a p53 dependent manner was shown to regulate p21 transcription. Whether H2A.Z is involved in p21 activity in the absence of p53 is not known. The p21 gene is repressed in estrogen receptor (ER) negative cell lines that are p53-/- and hormone independent for their growth. Here we demonstrate that class I and II pan Histone deacetylase inhibitors (HDACi) induce p21 transcription and reduce cell proliferation of MDA-MB231, an ERα-negative mammary tumor cell line, in a H2A.Z dependent manner. H2A.Z is associated with the transcription start site (TSS) of the repressed p21 gene. Depleting H2A.Z did not lead to transcription of p21 but annihilated the stimulating effect of HDACi on this gene. Acetylation of H2A.Z but not of H3K9 at the p21 promoter correlated with p21 activation. We further show that HDACi treatment reduced the presence of the p400 chromatin remodeler at the p21 TSS. We propose a model in which association of p400 negatively affects p21 transcription by interfering with acetylation of H2A.Z.

Indexed as

AcetylationBlotting, WesternBreast NeoplasmsCell Line, TumorCell ProliferationCell SurvivalCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsDNA HelicasesDose-Response Relationship, DrugEstrogen Receptor alphaHeLa CellsHistone Deacetylase InhibitorsHistonesHumansHydroxamic AcidsCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21DNA-Binding ProteinsDNA HelicasesEP400 protein, humanEstrogen Receptor alphaHistone Deacetylase Inhibitorshistone H2A.F-ZHistonesHydroxamic AcidsIndolesPanobinostatTumor Suppressor Protein p53

Identifiers

PMID23349794
PMCPMC3548890
OpenAlexW2009511470

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.